A growing specialist contract organization, hVIVO—a subsidiary of Open Orphan plc—has been tapped by Cocrystal Pharma to conduct a phase 2a clinical trial of its novel broad-spectrum, orally administered antiviral candidate, CC-42344.
Housed in hVIVO’s state-of-the-art facility in the United Kingdom, the trial has been designed to evaluate safety, viral and clinical measures of CC-42344 orally administered to patients who are infected with influenza A. The trial is still pending approval from the United Kingdom Medicines and Healthcare Products Regulatory Agency, but is expected to begin in late 2023.
Open Orphan (LON:ORPH) was founded in 2017, with the goal of rapidly building Europe’s leading pharma services company by a management team with extensive industry and financial expertise. The company comprises of two commercial specialist CRO services businesses (Venn Life Sciences and hVIVO) and is also developing a genomics data platform business (Genomic Health Data).